Business Context and Reporting Period
This Form 8-K, dated July 14, 2026, reports the completion of a material definitive agreement and asset acquisition by Ligand Pharmaceuticals Incorporated (Ligand). The filing details the consummation of the previously announced merger with XOMA Royalty Corporation (XOMA Royalty) and the simultaneous entry into a new credit facility.
Key Financial Metrics and Transaction Terms
- Merger Consideration: XOMA Royalty shareholders received $39.00 per share in cash plus Contingent Value Rights (CVRs) representing a right to future payments derived from a trust holding 75% of XOMA Royalty LLC.
- Preferred Stock Redemption: All outstanding Series A (8.625%) and Series B (8.375%) Perpetual Preferred Stock of XOMA Royalty were redeemed with accrued dividends.
- Debt Facility: Ligand entered into an Amended and Restated Credit Agreement providing a $125.0 million revolving credit facility maturing on September 12, 2028.
- Interest Rates: Borrowings accrue interest at Term SOFR or Base Rate plus margins ranging from 1.75% to 2.50% (SOFR) and 0.75% to 1.50% (Base Rate).
- Commitment Fees: Fees on unused commitments range from 0.300% to 0.450% based on leverage ratios.
Material Changes and Covenants
The transaction fundamentally alters Ligand's capital structure and debt obligations. Key financial covenants under the new Amended Credit Agreement include:
- Leverage Ratio: Maximum consolidated senior secured net leverage ratio of 2.50 to 1.00 (elective increase to 3.00 to 1.00 for four quarters following a material permitted acquisition).
- Minimum EBITDA:
- $100 million for the trailing four-quarter period from June 30, 2026, through March 31, 2027.
- $150 million for trailing four-quarter periods ending on or after June 30, 2027.
- Restrictive Covenants: Limitations on incurring additional indebtedness, liens, investments, restricted payments, and fundamental business changes.
Outlook, Risks, and Contingencies
Management Commentary: The filing confirms the successful closing of the merger and the restructuring of XOMA Royalty into a holding company prior to the merger. The CVR Spin mechanism was executed to distribute contingent value rights to former XOMA Royalty shareholders.
Risks and Contingencies:
- Events of Default: The credit agreement includes standard events of default (non-payment, breach of covenants, cross-defaults, change of control) which could trigger acceleration of debt.
- Bankruptcy Acceleration: Outstanding principal and interest automatically accelerate upon an order for relief under bankruptcy or insolvency laws.
- Future Filings: Financial statements of the acquired business and pro forma financial information are not included in this report and will be filed by amendment within 71 days.
Investor Verification Checklist
- Verify the final cash payout amount per share and the specific terms of the Contingent Value Rights (CVRs) in the CVR Trust Agreement.
- Review the upcoming Form 10-Q (due for the quarter ended June 30, 2026) for the full text of the Amended Credit Agreement and the pro forma financial impact of the merger.
- Monitor Ligand's ability to meet the new minimum consolidated EBITDA thresholds ($100M initially, rising to $150M) to avoid covenant breaches.
- Confirm the treatment of XOMA Royalty's equity awards and warrants as detailed in the Merger Agreement.